Compare PFBC & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFBC | EVO |
|---|---|---|
| Founded | 1991 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 1998 | 2021 |
| Metric | PFBC | EVO |
|---|---|---|
| Price | $94.51 | $3.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $104.67 | $7.00 |
| AVG Volume (30 Days) | 69.2K | ★ 99.6K |
| Earning Date | 10-20-2025 | 11-05-2025 |
| Dividend Yield | ★ 3.18% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 9.87 | N/A |
| Revenue | $271,347,000.00 | ★ $887,396,457.00 |
| Revenue This Year | $3.09 | N/A |
| Revenue Next Year | $3.60 | $10.78 |
| P/E Ratio | $9.57 | ★ N/A |
| Revenue Growth | ★ 4.21 | N/A |
| 52 Week Low | $71.90 | $2.84 |
| 52 Week High | $99.45 | $5.10 |
| Indicator | PFBC | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 60.85 | 49.54 |
| Support Level | $88.89 | $2.89 |
| Resistance Level | $96.00 | $3.24 |
| Average True Range (ATR) | 1.88 | 0.09 |
| MACD | 0.40 | 0.04 |
| Stochastic Oscillator | 77.50 | 95.65 |
Preferred Bank is a commercial bank located in California. Its products and services are divided into Personal Banking, Business Banking, and Commercial Banking which includes Checking accounts, Savings accounts, CDs, Loans and Credit, Electronic banking, and Treasury Management. It provides personalized deposit services, real estate finance, commercial loans, and trade finance credit facilities to small and mid-sized businesses and their owners, entrepreneurs, real estate developers and investors, professionals, and high-net-worth individuals. The bank generates a majority of its revenue from Southern and Northern California and Flushing.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.